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Neuroimaging measures of treatment effects would thus be a 
very welcome, more objective, addition to the presently largely 
subjective outcome measures.
We will focus on studies that tried to utilise neuroimaging to 
understand the pathophysiology of mental disorders by identifying 
cognitive tasks acting as a surrogate marker (e.g., working memory 
in schizophrenia, theory of mind in autism), those that compared 
different diagnostic or at-risk groups in order to obtain diagnostic 
or prognostic markers, and those that integrated neuroimaging in 
treatment protocols.
UNDERSTANDING PATHOPHYSIOLOGY
There are essentially three ways to employ neuroimaging to help 
unravel the pathophysiology of mental disorders. Functional neu-
roimaging data can be obtained while patients experience symp-
toms in order to elucidate the neural circuits involved. In some 
cases, investigators will wait for symptoms to occur and ask patients 
to report them online while under investigation. Where possible 
and ethically admissible, symptoms can also be induced, allowing 
for more controlled experimental conditions. This approach may 
sometimes entail a reduction of ecological validity, and the suc-
cessful symptom induction has to be checked with psychometric 
or psychophysiological measures. The discovery of primary audi-
tory cortex activity, embedded in a wider network of language and 
limbic areas (Dierks et al., 1999), during auditory verbal hallucina-
tions is an example for the former approach, the demonstration of 
amygdala activity in response to images of spiders in patients with 
arachnophobia (Dilger et al., 2003) or the provocation of panic 
attacks in patients with panic disorder by application of triggering 
substances (e.g., Zwanzger et al., 2009) for the latter. The identiﬁ  ca-
tion of these symptom-related regions and networks may inform 
treatment, for example targeted interference with transcranial mag-
netic stimulation (TMS), as shown for example with a NIRS-guided 
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Psychiatric diseases are mainly diagnosed by their symptoms, with 
little contribution from observable signs and none from biologi-
cal markers so far. This places psychiatry in a unique position 
compared to other medical disciplines. Although a great deal of 
information about disease mechanisms can be garnered from 
animal models, the neural correlates of the deﬁ  ning symptoms 
will ultimately have to be investigated in humans with the diverse 
techniques of neuroimaging. These techniques are mainly com-
puterized tomography (CT) and magnetic resonance imaging 
(MRI) in different variations at the structural level, and functional 
magnetic resonance imaging (fMRI), positron emission tomog-
raphy (PET), single photon emission computerized tomography 
(SPECT), near-infrared spectroscopy (NIRS), magnetoencepha-
lography (MEG) and electroencephalography (EEG)/event-related 
potentials (ERP) at the functional level. The assessment of the 
brain pathophysiology underlying psychiatric diseases constitutes 
a challenge and an opportunity for the techniques of human neu-
roimaging because they are well-placed to unravel the structural 
and functional correlates of psychiatric symptoms in the brain. 
Moreover, they may reveal changes in information processing that 
precede the onset of the clinical disorder and thus provide markers 
of risk or prognosis.
Diagnostic uncertainty is another perennial problem of psy-
chiatry and includes the uncertainty about the very existence 
of the nosological entities in use. Classical concepts of mental 
disorders such as schizophrenia have been variously attacked as 
being too broad or too narrow. Here, the hope is that neuroim-
aging may contribute diagnostic markers to support or refute 
existing categories. Finally, the monitoring of treatment effects 
is notoriously difﬁ  cult in psychiatry. The standard approach 
relies  heavily on changes on standardised psychopathological 
scales, which are based on the patients’ reports on their  symptoms. 
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repetitive TMS treatment protocol in a patient with panic disorder 
targeted on a frontal brain region implicated in emotion processing 
(Dresler et al., 2009). However, one needs to keep in mind that these 
pathological activations are disease-speciﬁ  c only in the rare cases 
where a disease is deﬁ  ned by a single symptom and this   symptom 
does not feature in other nosological categories (as is the case for 
arachnophobia, but not, for example, auditory hallucinations, 
Linden, 2008a).
However, we have to be careful with causal inferences from 
observations of regional brain activity during experience of speciﬁ  c 
symptoms. Such brain activity might reﬂ  ect a consequence of the 
symptom (e.g., fear evoked by the experience of hallucinations, or a 
shift of attention to the auditory domain) or compensatory mecha-
nisms (e.g., when patients try to suppress a symptom). Moreover, 
even if and when one can relate the existence of the symptom 
directly to the observed neural activity (e.g., by disrupting it with 
TMS and thus suppressing the symptom), the symptom could be 
driven by some upstream process. The ﬁ  nding of fronto-temporal 
activation during auditory hallucinations might serve as a case in 
point. This activation may produce the perceptual experience of 
voice hearing but may not in itself be abnormal. The reason that 
such internally generated speech is perceived as real (rather than 
imagined) voices might be in a deﬁ  cient monitoring mechanism 
with a different neural substrate.
Pathological activation patterns in mental disorders may not 
be conﬁ  ned to symptomatic periods. We assume for most mental 
disorders that they actually persist beyond the acutely  symptomatic 
state, and many have a remitting-relapsing course. Some traces 
of the disorder should therefore also be detectable during symp-
tom-free or remitted intervals. A second way of investigating 
pathophysiology with imaging is therefore through measurement 
of structural or functional trait markers that do not depend on 
a particular state. The analysis of functional connectivity during 
the “resting state” (which may be considered as a particular task 
as well) falls in this category, as does the comparison of cortical 
  volume or thickness between patients, individuals at genetic risk, 
and healthy controls, or the longitudinal investigation of functional 
or structural brain changes across phases of a disease (Takahashi 
et al., 2009). The ﬁ  ndings of structural imaging in areas such as 
cortical thickness or anatomical connectivity, as investigated by dif-
fusion tensor  imaging, may inform about the propensity to develop 
certain symptoms (Rotarska-Jagiela et al., 2009).
The third way utilises surrogate markers to obtain measures 
of brain activation that allow inferences about the underlying 
pathophysiology. Examples of frequently employed surrogate 
markers are working memory for schizophrenia, theory of mind 
for autism, emotional face processing for affective disorders and 
cognitive control paradigms for attention deﬁ  cit/hyperactivity dis-
order (ADHD, e.g., Fallgatter et al., 2005). The second and third 
approach can be complemented by other biological techniques 
that probe trait markers of mental disorder. The rapidly develop-
ing ﬁ  eld of genetic imaging (ﬁ  rst application in Fallgatter et al., 
1999), where functional or structural measures are  combined with 
functional polymorphisms or other genetic variants, is the most 
prominent example of such a methods combination, but other 
stable individual traits, such as eye movement patterns (Klein 
and Ettinger, 2008) can also be applied. Genetic imaging has, for 
example,   provided insight into the mechanism through which 
the dopamine system may exert inﬂ  uences on working memory 
(Herrmann et al., 2007; Diaz-Asper et al., 2008) or the serotonin 
system on emotion processing (Hariri et al., 2002; Hariri and 
Weinberger, 2003). It has also been suggested that some of the 
structural changes seen in groups of patients with mental disorders 
are mediated by functional variants in growth factors, for example 
Brain Derived Neurotrophic Factor (BDNF; Frodl et al., 2007). 
This approach can proceed in two directions, starting from a gene 
that has been associated with a particular disorder in a linkage or 
association study (for example, dysbindin (Fallgatter et al., 2006) 
or ZNF804A (O’Donovan et al., 2008) with schizophrenia), or 
starting from a gene that impacts on a biochemical mechanism 
implicated in the pathophysiology of mental disorders (Canli and 
Lesch, 2007). If starting from a gene with a known association 
with a disorder but an unknown function, this approach can pro-
vide the ﬁ  rst glimpses into its pathophysiological role (Esslinger 
et al., 2009). Conversely, starting from a biochemical mechanism, 
this approach can help identify intermediate phenotypes, such 
as heightened amygdala response or impaired working memory, 
which can then be further investigated for their association with 
mental disorders. However, in both cases the diagnostic speciﬁ  city 
will be low, because there are commonly many more participants 
with the at-risk polymorphism who do not suffer from the disorder 
than those who do, considering the relatively low prevalence rates 
and low relative risk afforded by these polymorphisms.
Finally, neuroimaging measures may also be considered as inter-
mediate phenotypes or endophenotypes which are more closely 
correlated with the fundamental (e.g., genetic) abnormalities of 
psychiatric disorders than the behaviour and the clinical symptoms 
themselves (see Figure 1).
Such neuroimaging endophenotypes may be applied as poten-
tial markers for the occurrence of hidden cognitive processes and 
provide evidence in favour of, or against, particular cognitive neu-
ropsychiatric models of symptoms. One could also envisage that 
such endophenotypic measures may help reﬁ  ne the distinction 
between symptoms that are very similar at the phenomenological 
level. For example, it is often difﬁ  cult in clinical practice to differ-
entiate delusions of schizophrenia from those of acute mania. If 
neuroimaging gave us speciﬁ  c patterns of regional/neurochemical 
activation during these states, it might help us improve the current 
diagnostic classiﬁ  cation systems and provide a more principled 
basis for the taxonomy of mental disorders.
IMPROVING DIAGNOSIS
Current diagnostic systems in psychiatry are mainly based on 
patients’ self-reports of symptoms and to some extent also on 
observed behaviour, and on their course over time. For exam-
ple, the criteria of the World Health Organisation’s International 
Classiﬁ  cation of Disease, 10th edition (ICD-10) for schizophrenia 
stipulate that at least one of the symptoms listed in Table 1 is present 
for 1 month. It becomes immediately clear that two patients can be 
diagnosed with schizophrenia without sharing any clinical features. 
Conversely they may have more in common with patients who 
fall into other diagnostic categories. For example a patient with 
symptoms from groups b and c may overlap more with a patient 
with bipolar affective disorder (BD) who is currently in a manic Frontiers in Human Neuroscience  www.frontiersin.org  December 2009  | Volume 3  |  Article 49  |  3
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Koutsouleris et al., 2009). In the absence of preventative treatments 
of affective disorders, Alzheimer’s disease or schizophrenia, the 
value of such information may be questioned. However, advocates 
of this line of research would argue that any investigation into the 
preventative properties of currently used (or new) pharmacological 
agents would need improved criteria for early detection and that 
these will probably have to include biological markers.
What, then, can neuroimaging contribute to the diagnosis of 
mental disorders? The main contribution of structural imaging in 
clinical practice is to exclude other causes that may lead to similar 
symptoms, such as space occupying lesions, cerebrovascular or 
inﬂ  ammatory disease, although the cost effectiveness of screening 
programmes has been debated (Albon et al., 2008). In the realm 
of severe mental illness, it is still not possible to identify patients 
with imaging ﬁ  ndings alone, or to differentiate between different 
disorders, as discussed below.
SCHIZOPHRENIA
One of the ﬁ  rst discoveries that were made with neuroimaging tech-
niques in any mental disorder was the enlargement of the  lateral and 
third ventricles in schizophrenia. This anatomical  characteristic was 
speciﬁ  c to patients with schizophrenia compared to their siblings, 
occurred at the onset of the disease and was associated with poorer 
treatment response. A recent study conﬁ  rmed the speciﬁ  city of ven-
tricular enlargement compared to affective psychosis (McDonald 
et al., 2006). Patients with schizophrenia as a group also show loss of 
local brain volume in numerous areas, including the language and 
auditory areas of the temporal lobe, the attention and visuomotor 
integration areas of the parietal lobe, the memory and executive 
areas of the frontal lobe, and parts of the limbic system and the 
basal ganglia. Such volume loss has been reported for schizophrenia 
patients already during adolescence and was found to progress 
at a rate of up to 4% per year (Toga et al., 2006). Furthermore, 
even patients with prodromal schizophrenia show limbic altera-
tions (Pantelis et al., 2003). However, at post-mortem there is often 
no difference in overall brain volume or that of structures impli-
cated in the pathogenesis of schizophrenia, e.g., the frontal lobes 
(Highley et al., 2001), between patients and age- and intelligence-
matched controls. Thus, brain degeneration does not progress at 
episode with psychotic features than with another schizophrenia 
patient who exclusively reports symptoms from group a. Against 
such a critique of the diagnostic validity of concepts such as “schizo-
phrenia” or “mania”, which is based on the cross-sectional overlap 
of symptoms, it can be maintained that commonalities and differ-
ences between the current diagnostic categories often become more 
apparent over time, in the natural history of symptoms and patterns 
of behaviour. However, even psychiatrists who believe in the useful-
ness of the current diagnostic concepts because of their predictive 
(common courses and treatment responses that differentiate, for 
example, bipolar disorder from schizophrenia) or genetic validity 
accept that additional diagnostic markers, derived from cognitive 
neuroscience or biology, would be of great importance.
Biological markers might also aid in the classiﬁ  cation of disor-
ders when the course is not yet known, for example to differentiate 
between unipolar depression and BD after a ﬁ  rst episode of depres-
sion (Phillips and Vieta, 2007). Finally, there is considerable hope 
that they might help predict the outbreak of a clinical disorder 
in people at risk who are identiﬁ  ed based on genetic (e.g., chil-
dren of patients with BD, Phillips et al., 2008), clinical (e.g., mild 
cognitive impairment, Prvulovic et al., 2005) or a combination of 
these criteria (e.g., the schizophrenia prodrome, Bender et al., 2007; 
FIGURE 1 | The endophenotype concept illustrated using the example of attention deﬁ  cit/hyperactivity disorder showing the way from genetic 
information to the levels of cell and systems function to a clinical phenotype. Additional inﬂ  uences by other factors may occur at every level.
Table 1 | Core symptoms of schizophrenia according to the ICD-10 
(quoted verbatim from http://www.who.int/classiﬁ  cations/icd/en/
bluebook.pdf, accessed on 8 July 2009). One symptom of this list, clearly 
present over at least one month, is sufﬁ  cient for the diagnosis to be made. 
a) Thought echo, thought insertion or withdrawal, and thought broadcasting.
b)   Delusions of control, inﬂ  uence, or passivity, clearly referred to body or 
limb movements or speciﬁ  c thoughts, actions, or sensations; delusional 
perception.
c)   Hallucinatory voices giving a running commentary on the patient’s 
behaviour, or discussing the patient among themselves, or other types of 
hallucinatory voices coming from some part of the body.
d)   Persistent delusions of other kinds that are culturally inappropriate and 
completely impossible, such as religious or political identity, or 
superhuman powers and abilities (e.g., being able to control the weather, 
or being in communication with aliens from another world).Frontiers in Human Neuroscience  www.frontiersin.org  December 2009  | Volume 3  |  Article 49  |  4
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episodes. However, the recent study by McDonald et al. (2006), 
which reported enlargement of lateral and third  ventricles in schizo-
phrenia, found no differences between psychotic BD patients and 
controls. The heterogeneity of the ﬁ  ndings across studies and the 
effect of age suggest that ventricle size, if altered in affective dis-
orders at all, would be a state rather than a trait marker. This view 
would be supported by the observation that relatives of patients 
with familial schizophrenia, but not those of patients with famil-
ial BD, also showed increased ventricles (McDonald et al., 2006). 
Similar ﬁ  ndings of lack of genetic association in BD have recently 
been reported for corpus callosum size (Walterfang et al., 2009).
Findings are also inconsistent across studies for most   cortical 
areas. Yet, some conﬁ  ned areas have been suggested by several studies 
to be reduced. The medial temporal lobe, particularly the hippoc-
ampus and the amygdala, has been speciﬁ  cally targeted by several 
volumetric studies because of the link between their  presumed func-
tion in emotion regulation and associative memory formation and 
the clinical symptoms of depression. Furthermore, an attractive 
aetiological model, largely based on animal studies, has implicated 
hippocampal damage due to stress in the brain processes of depres-
sion. However, ﬁ  ndings from structural imaging are inconsistent, 
with volume reductions, increases and no changes all being reported 
(Beyer and Krishnan, 2002). A recent report also suggests that hip-
pocampi are smaller already during adolescence in never medicated 
patients with early onset familial depression (MacMaster et al., 
2008). Yet, small hippocampi have also been observed in traumatised 
individuals without depressive symptoms (Karl et al., 2006), and this 
ﬁ  nding may thus be a non-speciﬁ  c consequence of stress rather than 
a speciﬁ  c feature of the pathophysiology of depression. In the basal 
ganglia, several studies reported a reduction of the volume of the 
striatum (caudate nucleus and putamen) mainly in elderly depressed 
patients. A link between basal ganglia pathology and depression is 
also suggested by the high occurrence of depression in Parkinson’s 
disease (up to 50%), but the apparent age effect would suggest that 
this may not be a primary pathology of psychiatric depression but 
an effect of the disease and/or medication, or a state marker of 
depression in the elderly.
Research in the 1980s suggested that a subgroup of patients with 
depression is suffering from increased secretion of cortisol and 
other signs of dysregulation of the hypothalamic-pituitary-adrenal 
(HPA) axis. This line of research has recently attracted renewed 
interested because of the HPA-stress model of depression, which 
will be discussed below. Structural imaging lent some support to 
changes in the HPA in depression. Both the adrenal gland and the 
pituitary were found to be enlarged in patients with depression, 
but it is as yet unknown whether this would normalise again after 
successful treatment or remission. In any case, as with most changes 
in the HPA axis, it will be difﬁ  cult if not impossible to determine 
whether they are aetiological factors of depression or correlates 
of the stress resulting from depression, unless they are found in 
subjects with genetic risk but no clinical symptoms.
TREATMENT EFFECTS
Although the best outcome measures of a psychiatric or 
  psychological intervention will always be at the level of the clini-
cal phenotype – for example, improvement of mood in a case of 
that pace across the lifetime in most schizophrenia patients. In sum, 
although several structural measures, including reduced whole-
brain volume, enlarged ventricles, reduced hippocampal volume 
and reduced asymmetry of the temporal plane, have been associated 
with schizophrenia (Kwon et al., 1999; McCarley et al., 1999; Gur 
et al., 2007), the overlap between patients and healthy controls is 
too large for them to attain the speciﬁ  city and sensitivity required 
for a diagnostic marker.
AFFECTIVE DISORDERS
Affective disturbance is perhaps the most frequent and most often 
neglected psychiatric manifestation of neurological disease, and thus 
of great clinical relevance beyond the ﬁ  eld of classical mental disor-
ders. Affective disturbance secondary to neurological disorders could 
also potentially provide clues as to the brain areas whose dysfunction 
leads to depression. Depressive symptoms occur frequently (in up to a 
third of cases) in stroke, traumatic brain injury or brain tumour, par-
ticularly those affecting the frontal lobe and basal ganglia. Although 
such ﬁ  ndings could potentially provide a lead to the role of these 
areas in maintaining emotional balance, caution is warranted for a 
number of reasons. The depressive syndrome is inherently heteroge-
neous, and focal lesions may predominantly produce symptoms that 
can be part of this  syndrome, but also occur during a range of other 
mental disorders, for example psychomotor slowing and apathy after 
frontal lesions. Moreover, multiple sclerosis, a disorder with a diffuse 
lesion pattern and predominantly white matter pathology, can also 
present with depression early on. The same is true for system illnesses 
affecting the brain such as acquired immunodeﬁ  ciency syndrome, 
thyroid disease or even heart failure (e.g., Angermann et al., 2007). 
Thus, a wide range of different lesion patterns affecting both gray and 
white matter can produce depressive symptoms, calling any straight-
forward structure-function relationship into question. Finally, the 
interpretation of affective changes in severely disabling neurological 
disorders is complicated by the occurrence of adjustment disorders 
with depressive symptoms, which are probably linked more directly 
with the dysfunctional coping mechanisms of the patient than with 
the function of the lesioned brain area.
There is thus very little basis to expect that evidence from neu-
ropsychiatric cases of depression will highlight the brain areas that 
are involved in classical psychiatric depression as well. However, 
there are a number of structural imaging ﬁ  ndings from patients 
with unipolar or bipolar depression, which are worth considering. 
Evidence for ventricular enlargement is weaker in affective disor-
ders than in schizophrenia, and a considerable number of studies 
found no difference between patients and controls. Elderly patients 
with depression have so far been the only group were a sizeable 
majority of studies have reported enlarged lateral ventricles (Beyer 
and Krishnan, 2002), and most studies in BD converge to suggest 
enlarged third ventricles. Strasser et al. (2005) found ventricular 
enlargement in schizophrenia and BD patients, but only those 
with the psychotic subtype. Volume losses in medial thalamic or 
hypothalamic areas that form the walls of the third ventricle have 
been suggested to underlie this enlargement. A possible implication 
of the hypothalamus would be of particular interest because of the 
prominent somatic and autonomic symptoms, for example the 
disturbed circadian clock, present during both depressed and manic Frontiers in Human Neuroscience  www.frontiersin.org  December 2009  | Volume 3  |  Article 49  |  5
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depression – these are sometimes difﬁ  cult to deﬁ  ne or obtain, 
especially for not primarily symptom-focussed techniques. This 
difﬁ  culty and the unreliability of self-report measures have trig-
gered a quest for biological or physiological markers of treatment 
responses. Such markers could be obtained by psychophysiology 
(e.g., galvanic skin response to emotional pictures), biochemistry 
(e.g., basal cortisol levels), neurophysiology (e.g., changes in the 
P100 or P300 components of the visual event-related potential, 
Fallgatter et al., 2003; Haenschel et al., 2007), receptor mapping 
(e.g., changes in striatal dopamine receptor occupancy, Hiemke, 
2008), or, functional neuroimaging with fMRI, SPECT, PET, or 
NIRS. The attraction of functional neuroimaging is that it pro-
vides a means of assessing metabolism or activation of individual 
brain regions, which confers an advantage compared to more global 
(biochemical or psychophysiological) measures where treatment 
effects are expected to operate through modiﬁ  cations of speciﬁ  c 
pathophysiological nodes. For example, if spider phobia is indeed 
caused by hyperactivation of the limbic system (Dilger et al., 2003), 
a successful intervention should lead to a reduced response of 
  implicated areas to the triggering stimulus.
Treatment monitoring with functional neuroimaging has had 
particularly fascinating applications in the ﬁ  eld of psychological 
interventions. One interesting aspect of this approach was that 
it had to overcome longstanding mutual reservations on the part 
of psychotherapists and neuroscientists. We can now safely say 
that there has been a paradigm shift over the past 10 years to an 
integrated view of psychological and neurobiological models of 
mental illness and its treatment. We have recently reviewed the 
neuroimaging studies that investigated psychotherapy effects or 
compared psycho- and pharmacotherapy effects for anxiety dis-
orders and depression elsewhere (Linden, 2006, 2008b). Several 
studies of cognitive behavioural therapy for speciﬁ  c or social 
phobia indeed found decreased activity in limbic structures 
(Furmark et al., 2002; Paquette et al., 2003; Straube et al., 2006) 
after successful treatment. The relationship between psycho- and 
pharmacotherapy can be studied best in disorders where both 
approaches are equally potent and commonly used. For exam-
ple, in the study of social phobia a similar reduction in medial 
temporal lobe activity during  preparation of a public speech was 
observed in the CBT and antidepressant treated groups (Furmark 
et al., 2002).
What contribution can functional neuroimaging then make to 
the treatment of mental disorders? We suggest three lines of investi-
gation and potentially practical implementation (Linden, 2008c):
(a)  Understand the mechanisms of neural plasticity that can be 
utilised in psychological and pharmacological interventions.
(b)  Compare neural changes during different types of interven-
tion (psycho- vs. pharmacotherapy and between different 
psychological interventions). It may ultimately become pos-
sible to identify likely responders to different types of therapy 
by their baseline patterns of neural activation, allowing for 
an individualized therapy. A word of caution is needed here 
because this aim has not been fulﬁ  lled in over a decade of 
functional imaging of pharmacotherapy, and reﬁ  ned psycho-
pathological criteria may be at least as promising.
(c)  Provide information about the pathophysiological nodes 
that may become the targets for physical (TMS, deep brain 
stimulation: DBS) or neurofeedback intervention.
DEVELOPING NEW THERAPIES
Functional imaging results have inﬂ  uenced or even motivated vari-
ous physical treatment approaches. The ﬁ  nding of auditory cortex 
activity during hallucinations has already led to partly successful 
attempts at attenuating hallucinations with TMS over the temporal 
lobe (Hoffman et al., 2003; Jandl et al., 2006). In affective  disorders, 
attention has focused on the subgenual area of the medial fron-
tal lobe, where both volume and metabolism were found to be 
reduced (Drevets et al., 1997). However, when metabolic activity 
was corrected for the partial volume effect, it appears to be higher in 
depressed patients compared to controls and revert to normal after 
effective treatment. This area has been the target of a recent DBS 
study with treatment refractory depressed patients (Lozano et al., 
2008), but its clinical effects still await conﬁ  rmation by a control-
led trial. The recent ﬁ  nding of contradictory treatment effects in 
the same brain area (Kennedy et al., 2007) also underlines that one 
has to be careful in associating a complex syndrome with a single 
putative area of hyperactivity.
Another interesting development driven by the advances of fMRI 
is the self-regulation of brain activity through neurofeedback. This 
technique consists in training participants to inﬂ  uence the neural 
signal from a target area while they receive online information about 
the amplitude of this signal (Weiskopf et al., 2003; deCharms, 2007; 
Johnston et al., 2010). The rationale for its therapeutic application can 
perhaps be based on the analogy with hypnosis. Hypnotic suggestions 
can attenuate somatosensory cortex and amygdala activity as well as 
pain perception (Röder et al., 2007). It should therefore be possible in 
principle for participants to produce similar changes themselves, for 
example by speciﬁ  c imagery strategies. FMRI-neurofeedback, target-
ing the anterior cingulated cortex, has indeed shown some prelimi-
nary success in chronic pain (deCharms et al., 2005). However, any 
application in complex psychiatric disorders probably would have to 
integrate neurofeedback in a comprehensive biopsychosocial inter-
vention package, as one would with classical biofeedback or relaxa-
tion techniques. However, if we believe that dysfunctional activity in 
speciﬁ  c areas or networks of the brain makes a causal contribution to 
mental illness, the ability to self-regulate these areas should ultimately 
have a beneﬁ  cial effect on a person’s mental health.
CONCLUSION
Functional and structural neuroimaging are key techniques of 
modern brain research and play a major role in the quest for bio-
logical markers of mental disorders. Although they have already 
contributed greatly to our understanding of the pathophysiology of 
mental disorders and their associated symptoms, clinical applica-
tions in diagnosis or treatment monitoring are still sparse. However, 
they may become more widespread once more information about 
the reliability and diagnostic speciﬁ  city of neuroimaging changes 
becomes available. Neuroimaging is also likely to assume increasing 
importance as a tool to monitor and compare the brain effects of 
different psychiatric and psychological treatments, and eventually 
aid in the development of new interventions.Frontiers in Human Neuroscience  www.frontiersin.org  December 2009  | Volume 3  |  Article 49  |  6
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